Cordlife Group (P8A) AI Stock Analysis

3 Followers

Cordlife Group

(SGX:P8A)

Select Model

Rating:42Neutral

Price Target:SGD 0.09▼(-4.40% Downside)

Action:reiterated

Date:10/31/26

The score is held down primarily by weak financial performance (ongoing losses and negative free cash flow) and very bearish technicals (below all major moving averages with negative MACD and extremely low RSI). The low-leverage balance sheet provides some stability, but valuation is not meaningfully supportive given the negative P/E and no dividend yield data.

Positive Factors

Low LeverageVery low leverage and a sizable equity base reduce solvency pressure and provide financial flexibility while the company works to restore profitability. This conservative funding structure can help Cordlife sustain operations and pursue improvement without relying heavily on additional borrowing.

Negative Factors

Persistent LossesPersistent operating and net losses show that the current business model is not yet converting revenue into sustainable earnings. The deeply negative net margin can erode equity over time and limits internal funding for service development, operational investment, or expansion.

Cordlife Group (P8A) vs. iShares MSCI Singapore ETF (EWS)

Market Cap: SGD 32.88M
Dividend Yield: ―
Average Volume (3M): 6,853
Price to Earnings (P/E): -2.2
Beta (1Y): 0.04
Revenue Growth: ―
EPS Growth: ―
Country: Singapore
Employees: 596
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Cordlife Group Business Overview & Revenue Model

Company Description

Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its opera...

How the Company Makes Money

Cordlife primarily earns revenue by providing stem cell banking services, typically structured around (1) an upfront service fee covering enrolment, collection kits, logistics, laboratory processing, testing, and cryopreservation setup, and (2) recur...

Cordlife Group Financial Statement Overview

Summary

Overall financials are pressured by ongoing losses and negative cash generation. The income statement remains loss-making with a ~-29% net margin and only modest TTM revenue growth (~+2%) versus a much higher 2021–2023 run-rate. Cash flow is also negative (TTM operating cash flow and free cash flow below zero), though losses and burn have moderated versus 2024–2025. The balance sheet is a relative strength with very low leverage (debt-to-equity ~0.04) and substantial equity (~100M), reducing solvency risk.

Income Statement

28Negative

Balance Sheet

72Positive

Cash Flow

34Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	36.96M	38.85M	27.84M	55.73M	55.16M	56.67M
Gross Profit	20.94M	21.75M	11.73M	37.30M	37.19M	39.48M
EBITDA	-8.60M	-10.16M	-14.38M	8.56M	9.34M	10.78M
Net Income	-10.69M	-12.64M	-18.69M	3.52M	4.89M	6.13M
Balance Sheet
Total Assets	198.87M	201.76M	217.14M	228.46M	228.00M	233.71M
Cash, Cash Equivalents and Short-Term Investments	49.83M	51.70M	60.58M	65.01M	65.17M	64.63M
Total Debt	4.32M	1.34M	2.42M	3.50M	2.22M	2.97M
Total Liabilities	98.61M	97.28M	98.68M	92.81M	93.67M	97.02M
Stockholders Equity	100.08M	104.30M	118.21M	135.33M	134.06M	136.43M
Cash Flow
Free Cash Flow	-981.00K	-729.00K	-15.62M	6.96M	5.32M	7.93M
Operating Cash Flow	-557.00K	504.00K	-11.31M	9.80M	7.71M	9.50M
Investing Cash Flow	10.13M	2.77M	-2.81M	-2.63M	4.43M	-23.91M
Financing Cash Flow	-2.91M	-2.10M	7.17M	-1.86M	-13.45M	3.37M

Cordlife Group Technical Analysis

Technical Analysis SentimentNegative

Last Price0.09

Price Trends

50DMA0.12Negative

100DMA0.13Negative

200DMA0.13Negative

Market Momentum

MACD-0.01Positive

RSI7.01Positive

STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:P8A, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.12, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 7.01 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:P8A.

Cordlife Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SG:P8A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SG:BSL	63Neutral	SGD 1.58B	23.22	6.42%	3.55%	-3.18%	6.71%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SG:A50	46Neutral	SGD 1.27B	-40.27	-6.42%	―	6.44%	38.89%
SG:P8A	42Neutral	SGD 23.23M	-2.18	-10.28%	―	―	―

* Healthcare Sector Average

Performance Comparison

SG:P8A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SG:P8A	Cordlife Group	0.09	-0.09	-49.44%
SG:BSL	Raffles Medical Group	0.84	-0.12	-12.80%
SG:A50	Thomson Medical Group Ltd.	0.05	-0.01	-21.67%
SG:40T	ISEC Healthcare Ltd	0.31	0.00	0.32%
SG:5WA	OUE Lippo Healthcare Limited	0.05	0.02	81.48%
SG:TBDD	Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh	1.52	0.01	0.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Cordlife Group AI Stock Analysis